Christopher Cabell insider trades

Open-market stock purchases and sales by Christopher Cabell, President & Head of R&D at Inhibikase Therapeutics, Inc, from SEC Form 4 filings since Jun 12, 2020.

Recent trades

DateStockTradeValue
Feb 21, 2026IKT Inhibikase Therapeutics, IncSold (not open market)—
Jan 5, 2026IKT Inhibikase Therapeutics, IncBought (not open market)—

Companies traded

  • IKT Inhibikase Therapeutics, Inc: other filings, last Feb 21, 2026
  • ZURA Zura Bio Ltd: other filings, last May 18, 2023
  • PULM Pulmatrix, Inc: other filings, last Jan 26, 2023
  • ARNA Arena Pharmaceuticals Inc: 1 sale, last Nov 25, 2020

Get free alerts when Christopher Cabell files a new trade →